Oric Pharmaceuticals Inc represents values of innovation, integrity, and collaboration. With a strong corporate philosophy, the company is dedicated to advancing the field of oncology through the development of novel therapeutics. Oric Pharmaceuticals Inc strives to improve patient outcomes by targeting the root causes of cancer and developing precision medicines. The company's commitment to scientific excellence, ethical conduct, and transparency drives their mission to deliver innovative solutions that address unmet medical needs. Oric Pharmaceuticals Inc embodies a patient-centric approach and fosters collaborations with leading researchers and institutions to accelerate the development of transformative cancer therapies.

Oric Pharmaceuticals Inc is primarily present in the United States. With headquarters located in Durham, North Carolina, the company focuses on developing innovative therapies for the treatment of cancer. As a leading pharmaceutical company, Oric Pharmaceuticals Inc has a strong presence in the United States, where it continues to research, market, and distribute its groundbreaking drugs. With a commitment to improving patient outcomes and transforming cancer treatment, Oric Pharmaceuticals Inc plays a vital role in the advancement of healthcare in the United States.

Oric Pharmaceuticals Inc has achieved several significant milestones in its history. Notably, the company successfully completed its initial public offering (IPO) in [year], raising [amount] in capital. In addition, Oric Pharmaceuticals Inc has advanced its innovative pipeline, focusing on the development of targeted therapies in the field of oncology. The company has also formed strategic collaborations with leading research institutions and pharmaceutical partners to accelerate drug discovery and development. Moreover, Oric Pharmaceuticals Inc has demonstrated promising results in preclinical and clinical studies, highlighting the potential efficacy of its therapies. These milestones reflect Oric Pharmaceuticals Inc's dedication to revolutionizing cancer treatment and its commitment to driving scientific advancements in the field.

Oric Pharmaceuticals Inc is a biopharmaceutical company based in the United States. Established in [year], the company focuses on developing innovative therapies for the treatment of cancer. With a mission to improve patient outcomes by targeting treatment-resistant cancers, Oric Pharmaceuticals has made significant strides in the field of oncology. The company's research and development efforts have resulted in the discovery of promising small molecule inhibitors, which show potential in overcoming resistance mechanisms in tumor cells. Oric Pharmaceuticals Inc has attracted attention from investors and garnered partnerships with renowned organizations, positioning itself as a leader in the fight against cancer.

The main competitors of Oric Pharmaceuticals Inc in the market include other pharmaceutical companies such as Pfizer, Johnson & Johnson, Novartis, and Merck. These companies are also actively involved in the development and commercialization of pharmaceutical products.

Oric Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Oric Pharmaceuticals Inc is focused on the development and commercialization of innovative therapies for the treatment of cancer. Oric Pharmaceuticals Inc leverages its expertise in cancer biology and drug discovery to identify and advance potential novel treatments that target specific cancer vulnerabilities. By employing a precision medicine approach, Oric Pharmaceuticals Inc aims to develop therapies that have the potential to improve patient outcomes and address unmet medical needs. With a strong commitment to research and collaboration, Oric Pharmaceuticals Inc strives to make significant advancements in the field of oncology and contribute to the fight against cancer.

Коефициентът на цена спрямо печалбата (КЦП) на Oric Pharmaceuticals е -3,92.

Коефициентът на цена към оборот (KUV) на Oric Pharmaceuticals е 0.

AlleAktien качественият резултат за Oric Pharmaceuticals е 2/10.

Приходите не могат да бъдат изчислени в момента за Oric Pharmaceuticals.

очаквана Oric Pharmaceuticals печалба е -130,03 млн. USD.

Oric Pharmaceuticals Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of cancer. The company's business model is based on identifying cancer types caused by specific gene mutations and developing drugs that target these mutations specifically. Oric has developed a proprietary platform technology called "OricOMP" that allows the company to selectively access cancer genes responsible for tumor cell growth. By identifying cancer types triggered by mutated genes, Oric can advance the development of highly specific and effective drugs. Oric's portfolio currently includes two products, Oric-101 and Oric-114, both of which are in clinical development. Oric-101 is an inhibitor of Protein Tyrosine Phosphatase 1B (PTP1B), an enzyme associated with insulin resistance. Oric-114, on the other hand, is an inhibitor of CD73, an enzyme associated with tumor-induced immunosuppression. Oric is also in the early stages of developing other drugs, including inhibitors of other cancer-associated target proteins. Furthermore, Oric's technology can continue to find applications in other disease areas by focusing on other mutated genes. Oric has also formed strategic partnerships with other companies in the industry, including AstraZeneca, to expand its pipeline of cancer drugs. Through these partnerships, Oric can leverage the capabilities and resources of other companies to accelerate the development and commercialization of new drugs. Oric's business model requires significant investment in research and clinical development to ensure its products meet the highest standards of safety and efficacy. The company utilizes its broad network of scientists, academics, and other industry experts to optimize its pipeline of compounds and unlock the potential of OricOMP in new areas of application. Oric aims to market its products globally to achieve maximum penetration in the markets. The company is focused on continuing the clinical development of Oric-101 and Oric-114 while also advancing the commercialization of its already approved drugs. Overall, Oric Pharmaceuticals Inc's business model is centered around the development of highly specific and effective cancer drugs that target cancer genes and mutations. The company will continue to invest in research and clinical development to optimize its pipeline of compounds and solidify its position as a leading company in cancer treatment.

Oric Pharmaceuticals разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Oric Pharmaceuticals в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Oric Pharmaceuticals е US68622P1093.

WKN на Oric Pharmaceuticals е A2P208.

Тикерът на Oric Pharmaceuticals е ORIC.

През последните 12 месеца Oric Pharmaceuticals изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Oric Pharmaceuticals да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Oric Pharmaceuticals в момента е .

Oric Pharmaceuticals изплаща дивидент на тримесечие. Той се разпределя в месеците .

Oric Pharmaceuticals платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Oric Pharmaceuticals се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Oric Pharmaceuticals на 13.09.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 13.09.2024 г..

Последното дивидентно плащане беше извършено на 13.09.2024 г..

През година 2023 Oric Pharmaceuticals изплати 0 USD под формата на дивиденти.

Дивидентите от Oric Pharmaceuticals се изплащат в USD.